CHICAGO (Reuters) - Allergan Inc said on Thursday that its popular Botox facial wrinkle-smoother worked as a treatment for adults suffering from chronic migraines, according to late-stage clinical ...

NEW YORK (Reuters) - Regulators seem inclined to approve Allergan Inc's wrinkle drug Botox to prevent migraine headaches in millions of Americans, industry analysts said, based on information the ...

Shares of Irvine-based Allergan Inc. jumped Monday as Wall Street got its first crack at the stock after word Friday that the company’s flagship Botox drug was approved as a treatment for migraine ...

Allergan has been working on a plan to hive off its women’s health and infectious disease units—much to the chagrin of some investors who were hoping the company would embrace a more drastic strategy ...

Facing competition for the world's top-selling drug, AbbVie is jumping on this year's pharmaceutical merger bandwagon with a $63 billion bid for Botox maker Allergan that's meant to spur future growth ...

Irvine-based Allergan Inc., maker of wrinkle-fighting Botox and other drugs, is gaining more attention on Wall Street. At least one analyst even crafted a pun—intended or otherwise—to lay out a case ...

For the second time in less than a year, the Food and Drug Administration has warned Irvine-based Allergan Inc. that advertisements for its anti-wrinkle drug Botox are misleading and should be pulled.

AbbVie and Allergan have waited expectantly to seal the deal on their $63 billion merger as international watchdogs took a close look at the combo. Now, they're almost home free. The EU says it's ...

Kimberly Horowitz is an international gem buyer specializing in diamonds, brokering deals in the hundreds of thousands of dollars. In her line of work, a confident, relaxed appearance can be the ...

DUBLIN, Nov. 18, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), the maker of BOTOX ® Cosmetic, has announced the first-ever National BOTOX ® Cosmetic Day kicking off on November 20. The celebration ...

(Reuters) - Allergan Plc on Tuesday forecast 2019 revenue below expectations on looming competition for some of its top drugs, and shelved plans to sell its women's health business. The Botox maker's ...